News

Gulf Times16d
Literary Partner: A Model for Sustainable Cultural and Economic Development
The Literary Partner Initiative (LPI), spearheaded by the Literature, Publishing and Translation Commission (LPTC) of Saudi Arabia, is subtly converting these spaces into vibrant hubs of ...
Zonebourse1mon
OSE Immunotherapeutics : des résultats positifs dans le traitement de la rectocolite hémorragique
OSE Immuntherapeutics a annoncé que plus de 90 % des patients souffrant de rectocolite hémorragique ayant atteint une réponse clinique après 10 semaines de traitement avec Lusvertikimab ont ...
Trading Sat1mon
Ose immuno: Invest Securities reste à l'achat
(CercleFinance.com) - La société a dévoilé les résultats à 34 semaines de son essai de Ph II CoTikiS évaluant OSE-127 dans la RCH (rectocolite hémorragique). Suite à cette annonce ...
Zonebourse1mon
OSE Immunotherapeutics : Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard - Au congrès annuel de l’AACR 2025
Une nouvelle signature d'expression génique pour prédire la réponse clinique aux points de contrôle immunitaires chez les patients atteints de cancer. Une signature qui peut améliorer le ...
Finanznachrichten1mon
OSE Immunotherapeutics: Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
NANTES, France - April 30, 2025, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology ...
Morningstar2mon
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
OSE-CYTOMASK®, a new CIS-Demasking1 cytokine bispecific technology. CLEC-1, a novel immune checkpoint target. NANTES, France – April 3, 2025, 6:00 p.m. CET - OSE Immunotherapeutics SA (ISIN ...
The American Journal of Managed Care3mon
Exploring Alternatives to LPI for Angle Closure Glaucoma
Traditional angle closure glaucoma management, including LPI, is being challenged due to limited evidence of efficacy in preventing visual field loss. The ZAP study suggests LPI's limited ...
The Star7mon
LPI Capital to tap into Public Bank’s network
PETALING JAYA: Analysts are mostly positive about LPI Capital Bhd ’s prospects, following the recent acquisition of the insurer’s 44.15% stake by Public Bank Bhd. LPI Capital posted a net ...
boursier.com8mon
OSE Immunotherapeutics SA présente OSE-CYTOMASK
OSE-CYTOMASK est une technologie propriétaire de liaison innovante, non clivable, permettant de créer une nouvelle classe de traitements à base de cytokines à activité régulée et ciblée ...
FierceBiotech10mon
OSE, flying solo after Servier split, suggests symptom improvements for ulcerative colitis prospect
OSE Immunotherapeutics is hoping to show Servier what they walked away from. Around one year after the French drugmakers split up, the biotech has reported midphase data on an anti-IL-7 antibody ...
The Star1y
LPI Capital expected to lead in fire class insurance market
PETALING JAYA: Despite LPI Capital Bhd ’s subdued sentiment from the industry’s de-tariffication in the fire class insurance segment, Kenanga Research says the group has potential to remain a ...